Professor Angela Cox
Professor of Cancer Genetic Epidemiology
Institute for Cancer Studies
Department of Oncology
The Medical School
Beech Hill Road
Telephone: +44 (0)114 271 2373
Facsimilie: +44 (0)114 271 1602
BA University of Cambridge 1983
PhD University College London 1991
1983-1984 Research Assistant, Unilever Research Laboratories, Bedford
1984-1991 Research Scientist, Celltech Ltd, Slough
1992-2000 Research Associate then Honorary Lecturer, Division of Genomic Medicine, University of Sheffield
2000-2011 Lecturer/ Senior Lecturer/ Reader, Institute for Cancer Studies, University of Sheffield
2011-present Professor of Cancer Genetic Epidemiology, Institute for Cancer Studies, University of Sheffield
My main interest is the use of statistical genetics and genetic epidemiology to identify genes that may be important susceptibility or survival factors for various cancers, by the analysis of candidate genes and genomic regions in population-based and family-based studies. The hypotheses we are testing are mainly concerned with genes whose proteins are involved in the DNA damage response and apoptosis pathways, in collaboration with Professor Mark Meuth and others in the Institute for Cancer Studies. Our aim is to determine the mechanisms of action of the genes to lead us towards novel drug targets and improved risk modelling.
We participate in various international genetics consortia including BCAC, PRACTICAL and COGs.
Our current research is funded by the National Cancer Institute (NCI), Yorkshire Cancer Research (YCR), Cancer Research-UK (CR-UK) and Breast Cancer Campaign (BCC)
- MSc in Molecular and Genetic Medicine, Molecular Genetics of Human Diseases module.(6 lectures)
- BMS 379 Tumour Cell Biology (1 lecture)
- Post-graduate research lead for Department of Oncology
Camp NJ*, Parry P*, Knight S, Abo R, Elliott G, Rigas S, Balasubramanian SP, Reed MWR, McBurney H, Latif A, Newman WG, Cannon-Albright LA, Evans DG, Cox A.
Fine-mapping CASP8 risk variants in Breast Cancer.
Cancer Epidemiology, Biomarkers and Prevention 2012 21, 176-81.
Lin, W-Y., Camp, N.J., Cannon-Albright, L.A., Allen-Brady, K., Balasubramanian, S.P., Reed, M.W., Hopper, J.L., Apicella, C., Giles, G.G., Southey, M.C., Milne, R.L., Perez, J.I.A., Rodríguez, P.M., Benítez, J., Grundmann, M., Dubrowinskaja, N., Park-Simon, T-W., Dörk, T., Garcia-Closas, M., Figueroa, J., Sherman, M., Lissowska, J., Easton, D.F., Dunning, A.M., Rajaraman, P., Sigurdson, A.J., Doody, M.M., Linet, M.S., Paul D. Pharoah, P.D., Schmidt, M.K., and Cox, A.
A role for XRCC2 gene polymorphisms in breast cancer risk and survival.
J Med Genet 2011 48, 477-484
Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D.
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies.
PLoS Med 2010 7, e1000279.